Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Rapport Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 70 | 1 | 77 | +8 |
| Shares | 36.6M | 12.1K | 38.1M | +1.54M (+4.2%) |
| Value | $648.9M | $214.1K | $382.3M | −$266.4M (−41.1%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Rapport Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 457,556 | $4.59M | 0.15% |
| UBS Asset Management Americas Inc | 203,242 | $2.04M | 0.00% |
| Ensign Peak Advisors, Inc | 194,200 | $1.95M | 0.00% |
| Two Sigma Investments, LP | 33,757 | $338.6K | 0.00% |
| SummitTX Capital, L.P. | 26,830 | $269.1K | 0.01% |
| Susquehanna International Group, LLP | 24,471 | $245.4K | 0.00% |
| Nuveen, LLC | 21,873 | $219.4K | 0.00% |
| XTX Topco Ltd | 15,442 | $154.9K | 0.01% |
| Jump Financial, LLC | 13,760 | $138.0K | 0.00% |
| Two Sigma Advisers, LP | 12,000 | $120.4K | 0.00% |
| Catalyst Private Wealth, LLC | 10,000 | $100.3K | 0.05% |
| Virtus Investment Advisers, Inc. | 8,637 | $86.6K | 0.02% |
| US Bancorp | 144 | $1.44K | 0.00% |
| Signaturefd, LLC | 137 | $1.37K | 0.00% |
| Allworth Financial LP | 15 | $167 | 0.00% |
| Lindbrook Capital, LLC | 15 | $150 | 0.00% |
| True Wealth Design, LLC | 3 | $31 | 0.00% |
Sold out (9)
Institutions that held Rapport Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Perceptive Advisors LLC | 311,551 | $5.53M |
| Jennison Associates LLC | 62,287 | $1.10M |
| Norges Bank | 48,452 | $859.5K |
| Crestline Management, LP | 27,496 | $487.8K |
| LMR Partners LLP | 20,000 | $354.8K |
| Sandia Investment Management LP | 5,000 | $88.7K |
| Virtus ETF Advisers LLC | 3,740 | $66.3K |
| Nisa Investment Advisors, LLC | 18 | $319 |
| Aster Capital Management (DIFC) Ltd | 5 | $89 |
Not filed for Q1 2025 yet (1)
Institutions that held Rapport Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 12,068 | $214.1K |